Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2021-02-01
|
| Saila: | Molecules |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/1420-3049/26/4/944 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|